Association of a Serum Proteomic Signature With Survival and Immune-Related Adverse Events in Patients With NSCLC Treated With Immune Checkpoint Inhibitors

Background: Serum proteomic signatures may reflect tumor- and host-related biology and serve as prognostic biomarkers in patients receiving immune checkpoint inhibitors (ICIs). We evaluated the association of the VeriStrat serum proteomic classification with survival outcomes and immune-related adverse events (irAEs) in patients with non-small cell lung cancer (NSCLC) treated with ICIs. Methods: We retrospectively reviewed patients with NSCLC who received ICI-containing therapy and underwent VeriStrat testing at Northwestern Memorial Hospital from October 2015 through June 2023.